School of Basic Medical Sciences, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Guangzhou Medical University, Guangzhou, China.
Department of Radiology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Br J Pharmacol. 2022 Nov;179(21):4974-4991. doi: 10.1111/bph.15926. Epub 2022 Aug 3.
Macrophage-rich atherosclerotic arteries are highly active in glycolysis. PFKFB3, a key glycolytic enzyme, has emerged as a potential therapeutic target in atherosclerosis. Small-molecule inhibitors of PFKFB3, such as 3PO and PFK158, have demonstrated efficacy in hampering atherogenesis in preclinical models. However, genetic studies elucidating the role of Pfkfb3 in atherogenesis need to be conducted to validate pharmacological findings and to unveil potential pharmacological side effects.
Apoe mice with global heterozygous or myeloid cell-specific Pfkfb3 deficiency were fed a Western diet (WD), after which atherosclerosis development was determined. Monocyte subsets in atherosclerotic mice and patients were examined by flow cytometry. Monocyte infiltration was assayed by a Ly6C monocyte-specific latex labelling procedure. In situ efferocytosis was assessed on mouse aortic root sections. Additionally, metabolic status, macrophage motility, efferocytosis, and involved mechanisms were analysed in peritoneal macrophages.
Global heterozygous or myeloid cell-specific Pfkfb3 deficiency reduced atherogenesis in Apoe mice. Mechanistic studies showed that PFKFB3 controlled the proliferation and infiltration of proinflammatory monocytes. Moreover, PFKFB3 expression was associated with inflammatory monocyte expansion in patients with atherosclerotic coronary artery disease. Surprisingly, homozygous loss of Pfkfb3 impaired macrophage efferocytosis and exacerbated atherosclerosis in Apoe mice. Mechanistically, PFKFB3-driven glycolysis was shown to be essential for actin polymerization, thus aiding the efferocytotic function of macrophages.
Collectively, these findings suggest the existence of a double-edged sword effect of myeloid PFKFB3 on the pathogenesis of atherosclerosis and highlight the need for caution in developing anti-atherosclerotic strategies that target PFKFB3.
富含巨噬细胞的动脉粥样硬化血管在糖酵解中高度活跃。PFKFB3 是一种关键的糖酵解酶,已成为动脉粥样硬化的潜在治疗靶点。PFKFB3 的小分子抑制剂,如 3PO 和 PFK158,已在临床前模型中证明能有效阻碍动脉粥样硬化的形成。然而,需要进行阐明 Pfkfb3 在动脉粥样硬化形成中的作用的遗传研究,以验证药物学发现并揭示潜在的药物副作用。
载脂蛋白 E(Apoe)基因敲除小鼠存在全基因组杂合缺失或骨髓细胞特异性 Pfkfb3 缺失,给予西方饮食(WD)喂养,以确定动脉粥样硬化的发展情况。通过流式细胞术检测动脉粥样硬化小鼠和患者中的单核细胞亚群。通过 Ly6C 单核细胞特异性乳胶标记程序检测单核细胞浸润。在小鼠主动脉根部切片上评估原位吞噬作用。此外,还分析了腹腔巨噬细胞中的代谢状态、巨噬细胞迁移、吞噬作用以及涉及的机制。
全球杂合缺失或骨髓细胞特异性 Pfkfb3 缺失可减少 Apoe 小鼠的动脉粥样硬化形成。机制研究表明,PFKFB3 控制促炎单核细胞的增殖和浸润。此外,PFKFB3 的表达与动脉粥样硬化性冠心病患者中炎症性单核细胞的扩张有关。令人惊讶的是,Pfkfb3 纯合缺失会损害巨噬细胞的吞噬作用并加剧 Apoe 小鼠的动脉粥样硬化。从机制上讲,PFKFB3 驱动的糖酵解对于肌动蛋白聚合是必需的,从而有助于巨噬细胞的吞噬作用。
总的来说,这些发现表明骨髓细胞 PFKFB3 对动脉粥样硬化发病机制存在双刃剑效应,并强调在开发针对 PFKFB3 的抗动脉粥样硬化策略时需要谨慎。